Figure 1.
Flow chart of inclusion and exclusion criteria.
Of the 199 subjects, 73 were excluded and the remaining 126 were included in the study. The latter group was divided into the preemptive therapy group (n = 30) and the non-therapy group (n = 96).
Table 1.
Baseline demographics and laboratory data of patients who did and did not receive CMV preemptive therapy.
Figure 2.
Kaplan-Meier curve showing the time to development of cytomegalovirus (CMV)- end-organ disease (EOD) in the preemptive and non-preemptive therapy groups.
Compared to patients on CMV preemptive therapy, those who did not receive preemptive therapy were more likely to develop CMV-EOD (p = 0.027, Log-rank test).
Table 2.
Results of univariate analysis to estimate the risk of various factors in inducing CMV end-organ disease.
Table 3.
Results of multivariate analysis to estimate the preventive effect of CMV preemptive therapy against CMV end-organ disease.
Table 4.
Details of CMV end-organ disease.
Figure 3.
Kaplan-Meier curve showing the time to death in the preemptive and non-preemptive therapy groups.
There was no significant difference in the survival rate between the two groups (p = 0.193, Log-rank test).